Quanta obtains CE mark for portable, cartridge-based haemodialysis system

NewsGuard 100/100 Score

Quanta Fluid Solutions Ltd ("Quanta" or the "Company"), a pioneering developer of advanced haemodialysis systems, announces it has received the CE mark for SC+, its portable, cartridge-based haemodialysis system.

SC+ is designed to bring flexibility to dialysis patients and physicians by supporting all treatment regimens, from nurse-assisted care and patient self-care in-centre to home haemodialysis. SC+ is the only portable, compact haemodialysis system with the clinical efficacy and high flow rates of traditional in-centre machines. The technology behind SC+ is based on an innovative and unique design that incorporates all fluid management activities onto a single-use disposable cartridge.

Quanta is also pleased to announce that it has raised additional funds expanding its recent investment round to a total of £29 million. The round was led by new investor ALIAD, the venture capital investment vehicle of Air Liquide SA (Paris: AI), and included participation by additional new investors Seventure Partners and Kuwait Life Sciences Company, as well as existing investors Wellington Partners, Seroba Kernel, NBGI Ventures, b-to-v Partners and IMI plc (LSE: IMI).

John E. Milad, Chief Executive Officer of Quanta, said: "This is an exciting time for Quanta. Obtaining the CE mark for SC+ is a major milestone forus and is a testament to the ingenuity and engineering excellence of our team. SC+ is a revolutionary dialysis system based around a novel single-use disposable cartridge. Our system will provide meaningful benefits to patients and healthcare providers in terms of ease-of-use, flexibility and performance. 2014 was a transformational year for Quanta, and we are now strongly positioned to introduce SC+ for clinical use in 2015."

Professor John Agar, a practicing clinical nephrologist, Clinical Conjoint Professor of Medicine at Deakin University School of Medicine at the Geelong Hospital, Barwon Health and Member of Quanta's Medical Advisory Board, said: "Quanta's SC+ is the first real advance in dialysis system choice in a decade and a half. While small, light, and truly portable, it is still at its heart, a single pass dialysis system providing efficient and comparable dialysis to current technologies. SC+ has the benefit of transferability from centre to home, and from home to centre, which gives valuable and flexible treatment options for physicians, patients and care givers. This is a truly game-changing technology."

Source:

Quanta

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Evaluating the efficacy of harmol in treating herpes simplex virus-induced keratitis